Skip to main content

Table 1 Characteristics of included studies

From: The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression

First author, year

Country of origin

Study design

(Sub)group

Patients (n), completed PRO%

Age (mean ± SD)

Gender (% male)

CKD stage

(e)GFR ml/min/1,73m2(mean ± SD)

Kidney volume (mL), (mean ± SD or median (IQR))

Liver volume (mL) (mean ± SD or median (IQR))

Patient-reported outcome measure

Barros et al., 2011 [34]

Brazil

Cross-sectional

Non-dialysis

33 (100)

37 ± 12

24

1–4

69 ± NRa

NR

NR

State Trait Anxiety Inventory, Beck Depression scale, SF-36

Hogan et al., 2010 [35]

USA

Randomized controlled trial

All patients

34 (100)

50 ± 9

24

1–4

61 ± 22

852 (486–1430)

4969 (3258–8404)

SF-36

Keimpema et al., 2009 [36]

Netherlands

Randomized controlled trial

All patients

32 (97)

51 ± 9

13

1–4

64 ± 25

872 (502–1551)

4906 (3380–6416)

SF-36, Gastrointestinal symptom scaleb

Lee et al., 2003 [37]

USA

Longitudinal observational study

All patients

29 (28)

46 ± 14

24

1–4

NR

2276 (NR)

NR

SF-36

Miskulin et al., 2014 [13]

USA

Randomized controlled trial

All patients

1043 (99)

42 ± NR

50

1–4

68 ± NR

1215 ± NRc

1958 ± NRc

SF-36, Modified version of the Wisconsin Brief pain survey

   

eGFR 20–44

213

49 ± 8

50

3–4

37 ± 5

NR

NR

 
   

eGFR 45–60

221

47 ± 8

51

3

52 ± 5

1821 ± 1041

2225 ± 790

 
   

eGFR ≥ 60

609

37 ± 9

50

1–2

85 ± 18

1198 ± 711

1950 ± 800

 

Rizk et al., 2009 [16]

USA

Longitudinal observational study

All patients

152 (100)

44 ± 10

40

1–4

65 ± 33

937 ± 883

NR

SF-36

Simms et al., 2015 [38]

United Kingdom

Cross-sectional

All patients

139 (100)

49 ± 16

48

1–4

59 ± 33

NR

NR

KDQOL-SF1.3, Patient health questionnaire (PHQ-9), multidimensional scale of perceived social support (MSPSS), Sheffield ADPKD psychosocial risk instrument (Sheffield ADPKD PSRI) SF-36 and self-made symptom scale

   

eGFR Ë‚30

36

66 ± 13

47

4

18 ± 5

NR

NR

 
   

eGFR 30–60

38

56 ± 11

47

3

45 ± 8

NR

NR

 
   

eGFR > 60

65

45 ± 14

35

1–2

89 ± 19

NR

NR

 

Suwabe et al., 2013 [15]

Japan

Longitudinal observational study

Non-dialysis

111 (100)

52 ± 12

40

 

30 ± NRa

3308 ± 2566

3841 ± 3551

 

Temmerman et al., 2014 [39]

Belgium

Longitudinal observational study

 

50 (100)

51 ± 9

10

1–4

58 ± 24

1126 (586–1806)

4918 (3942–6360)

SF-36, Polycystic liver diseasecomplaint-specific-assessment (POLCA)

  1. CKD chronic kidney disease stage, NA not applicable, NR not reported, PRO patient reported outcome, SD standard deviation aCalculated based on serum creatinine with CKD-EPI formula bNo validated total score available cKidney and liver volumes only measured in patients with eGFR >45 ml/min
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us